6:13 PM
 | 
Sep 10, 2012
 |  BC Extra  |  Clinical News

Zalicus slides after dropping RA product

Zalicus Inc. (NASDAQ:ZLCS) fell $0.60 (43%) to $0.79 on Monday after discontinuing development of Synavive after it did not significantly reduce DAS28-CRP scores from baseline to week 12 vs. active comparator prednisolone in...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >